Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues grew 10%, excluding FX. Net earnings attributable to BMS were $1.21 billion, or $0.60 per share, compared to $1.92 billion, or $0.93 per share, last year. Adjusted EPS decreased 10% to $1.80. For […]
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues grew 10%, excluding FX. Net earnings attributable to BMS were $1.21 billion, or $0.60 per share, compared to $1.92 billion, or $0.93 per share, last year. Adjusted EPS decreased 10% to $1.80. For […]
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today.
Total revenues increased 8% year-over-year to $11.9 billion. Revenues grew 10%, excluding FX.
Net earnings attributable to BMS were $1.21 billion, or $0.60 per share, compared to $1.92 billion, or $0.93 per share, last year. Adjusted EPS decreased 10% to $1.80.
For the full year of 2024, BMY expects total revenues to increase around 5% YoY. Adjusted EPS is expected to be $0.75-0.95.
